Carol C. Lam - 19 Apr 2023 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role: Director
Signature: /s/ Scott B. Brown, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 19 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 21 Apr 2023, 20:52:54 UTC
Previous filing: 16 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TCON	Director Stock Option (Right to Buy)	Award	$0	+18,000		$0.000000	18,000	19 Apr 2023	Common Stock	18,000	$1.82	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders, subject to the optionee's Continuous Service (as defined in the Company's 2015 Equity Incentive Plan (the "Plan")) and accelerated on the closing of a Change of Control (as defined in the Plan).

Content

The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders, subject to the optionee's Continuous Service (as defined in the Company's 2015 Equity Incentive Plan (the "Plan")) and accelerated on the closing of a Change of Control (as defined in the Plan).